<DOC>
	<DOCNO>NCT00189670</DOCNO>
	<brief_summary>To screen dose-dense arm use future large scale phase III trial . Primary endpoint safety ; secondary endpoint disease free survival overall survival . A total 100 patient include .</brief_summary>
	<brief_title>Randomized Phase II Trial Dose Dense Docetaxel N+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patient histologically proven breast cancer Surgical resection perform clear margin ( R0 resection ) At least 1 histologically proven involved axillary node ER + ER Interval surgery ( 2nd surgical procedure case multiple procedure ) randomization inferior 60 day Aged 18 year , 10year life expectancy ECOG performance status 01 Signed inform consent form prior randomization Bilateral breast cancer Inflammatory breast cancer Personal history breast cancer Immunohistochemical node involvement Intraductal breast cancer Distant metastases Contraindication drug contain chemotherapy regimens Any serious active disease comorbid medical condition include recent history severe sepsis digestive inflammatory disease Poor renal function ( creatinin level &gt; 120 micromol/L ) , poor hepatic function ( total bilirubin level &gt; 1 UNL ) , transaminases &gt; 2.5 UNL ) Poor bone marrow reserve define neutrophil &lt; 1.5 G/L platelet &lt; 100 G/L ; Hemoglobin &lt; 10 G/dL Poor contractile cardiac function ( LVEF &lt; 50 % ) Coronary disease Any history cancer last 5 year , exception basal cell carcinoma stage 0 ( situ ) cervical carcinoma Pregnancy breast feed Absence contraception non menopausal woman Adult patient unable give inform consent intellectual impairment Concomitant participation another trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>